QPC Lasers receives $1.3 million in orders for cancer and medical therapeutic applications

January 16, 2008, Sylmar, CA--QPC Lasers has received $1.3 million in new orders of its BrightLase Ultra Lasers for use in medical applications. According to the company, these two new orders come less than a month after the launch of the BrightLase Ultra product line, and will be used in surgical and therapeutic applications. Shipments for the two orders commenced last month and are scheduled to be completed by the end of 2008.

"We continue to see strong customer interest in our new Ultra Lasers, particularly for surgical laser applications such as the treatment of cancerous tumors, benign prostrate hyperplasia, and cardiology where they show great promise because of the laser's ability to rapidly and precisely remove tissue in a sterile and minimally invasive fashion," said Paul Rudy, vice president of marketing and sales for QPC.

Ultra-500 Lasers were announced last month and utilize QPC's proprietary semiconductor laser chip technology, offering increased power and industry leading brightness. For industrial customers, the BrightLase Ultra-500 provides over 400 W at near infrared wavelengths from an energy-efficient, reliable and cost-effective package critical for laser micro-welding, engraving and marking applications. For defense customers, the BrightLock Ultra-500 is a high performance laser pump engine, featuring up to 180 W in a compact, lightweight footprint with a narrow stable emission spectrum designed for solid state and fiber laser systems.